Answers are grounded in this paper and cite their sources.
The nature and the size of the benzylic substituent are shown to be the key to controlling receptor selectivity (CCR5 vs M1, M2) and potency in the title compounds. Optimization of the lead benzylic methyl compound 3 led to the methoxymethyl analogue 30, which had excellent receptor selectivity and oral bioavailability in rats and monkeys. Compound 30 (Sch-417690/Sch-D), a potent inhibitor of HIV-1 entry into target cells, is currently in clinical trials.
No takes yet. Share an insight, caveat, or question.
Tagat et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: